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Abstract
Background: The adverse effects of growth hormone (GH) deficiency (GHD) in adults (AGHD) on metabolism and
health-related quality of life (HRQoL) can be improved with GH substitution. This investigation aimed to design a
score summarising the features of GHD and evaluate its ability to measure the effect of GH substitution in AGHD.
Methods: The Growth hormone deficiency and Efficacy of Treatment (GET) score (0–100 points) assessed (weighting):
HRQoL (40%), disease-related days off work (10%), bone mineral density (20%), waist circumference (10%), low-density
lipoprotein cholesterol (10%) and body fat mass (10%). A prospective, non-interventional, multicentre proof-of-concept
study investigated whether the score could distinguish between untreated and GH-treated patients with AGHD.
A 10-point difference in GET score during a 2-year study period was expected based on pre-existing knowledge
of the effect of GH substitution in AGHD.
Results: Of 106 patients eligible for analysis, 22 were untreated GHD controls (9 females, mean ± SD age 52 ± 17 years;
13 males, 57 ± 13 years) and 84 were GH-treated (31 females, age 45 ± 13 years, GH dose 0.30 ± 0.16 mg/day; 53 males,
age 49 ± 15 years, GH dose 0.25 ± 0.10 mg/day). Follow-up was 706 ± 258 days in females and 653 ± 242 days in males.
The GET score differed between the untreated control and treated groups with a least squares mean difference
of + 10.01 ± 4.01 (p = 0.0145).
Conclusions: The GET score appeared to be a suitable integrative instrument to summarise the clinical features
of GHD and measure the effects of GH substitution in adults. Exercise capacity and muscle strength/body muscle mass
could be included in the GET score.
Trial registration: NCT number: NCT00934063. Date of registration: 02 July 2009.
Keywords: Clinical study, Growth hormone, Growth hormone deficiency, Quality of life
Background
Growth hormone (GH) is a pleiotropic hormone. Whereas
growth failure is the relevant symptom of childhood GH
deficiency (GHD), adult GHD (AGHD) is a recognised
syndrome with adverse phenotypic, metabolic and health-
related quality of life (HRQoL) features [1], which improve
in many patients when GH is substituted [2, 3]. For some
chronic diseases with multiple clinical facets and compli-
cations (e.g., diabetes), a composite of clinical endpoints
has been defined as a primary outcome measure for study
purposes to evaluate the effect of therapeutic interven-
tions [4, 5].
The objective of this project was to design and, in a sec-
ond step, conduct a non-interventional proof of concept
study to evaluate an instrument that allows quantification
and summarising of the various facets of AGHD and the
therapeutic response to GH replacement. The composite
score was given the acronym “GET – Growth hormone
deficiency and Efficacy of Treatment” and aimed to pro-
vide a quantitative integrative picture of parameters that,
based on evidence in the literature [2, 3], are considered
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clinically, economically and socially relevant in a large
population.
All the parameters chosen to be integrated into the GET
score had previously been shown, according to the criteria
of evidence-based medicine (EBM), to be affected by
GHD and to be improved following GH substitution in
AGHD. The weighting of parameters in the GET score
was arbitrarily defined by the study group according to
their estimated clinical relevance (experts’ opinion). The
parameters are all assessed in routine clinical practice and
the composite score was intended to have the potential to
be used for scientific purposes as well as in clinical prac-
tice. In the second step of this project, a prospective, non-
interventional, multicentre proof of concept study was
performed to investigate whether the GET score was able
to distinguish between untreated and GH-treated patients
with AGHD. Based on existing knowledge regarding the
effect of GH replacement in patients with AGHD on the
parameters included in the score, the difference between
control and treated patients over 2 years was expected to
be 10 points, and this difference was assumed to be clinic-
ally relevant (see details in Methods). If this was shown,
the GET score would be considered a scientifically useful
and clinically relevant instrument. In addition, the effect
of GH therapy on insulin-like growth factor I (IGF-I)
standard deviation score (SDS) and on the individual clin-
ical parameters comprising the GET score was evaluated.
Methods
GET score assessment and definition
GET score items were selected according to evidence
available in the literature [2, 3], and their weighting was
defined arbitrarily following extensive discussion in the
study group. The GET score was designed to cover a range
between 0 and 100 points, composed from clinically meas-
urable parameters. It was intended that GH-untreated pa-
tients with AGHD should be positioned approximately in
the middle of the range (with a mean of ~ 50 points and a
standard deviation [SD] of ~ 20 points) and that the range
should allow the measurement of treatment effects. Fifty
percent of the GET score points were generated from
HRQoL parameters and 50% from physical measurements
of somatic parameters.
The Short-Form Health Survey 36 (SF-36), one of the
most commonly used generic instruments for measuring
HRQoL, covers eight HRQoL elements assessing phys-
ical and psychological health [6]. Previous research has
established the relationship between the EuroQol five di-
mensions questionnaire (EQ-5D), a generic five-item in-
strument providing a simple descriptive profile and a
single index value for health status, and a tool used to
measure HRQoL in patients with AGHD [7, 8]. An in-
crease in the SF-36 and EQ-5D visual analogue scale
(VAS) score reflects an improvement in self-perceived
health. The SF-36 and the VAS component of EQ-5D
(EQ-5D-VAS) have both been used previously in patients
with AGHD [7, 9]. The QoL-Assessment of GHD in
Adults (QoL-AGHDA), a disease-specific, need-based
measure [10], developed based on in-depth interviews
with adult patients with GHD is also a recognised meas-
ure for the assessment of QoL. However, restricted li-
cence use did not permit use of this tool in our study.
The HRQoL parameters of the GET score comprised the
SF-36 score [7] (20 points) and the EQ-5D-VAS (20 points),
together with the disease-related days off work (10 points).
Details on the allocation of the GET score points from
SF-36 and EQ-5D-VAS are given in Additional file 1:
Table S1. As the SF-36 covers eight dimensions, the
arithmetic mean of the score points from each dimen-
sion was taken and included into the GET score (an ex-
ample is shown in Additional file 1: Table S2). Based on
data from Saller et al., [11] > 30 disease-related days off
work during the previous 6 months generated a score of
0 points, and < 4 disease-related days off work generated
a score of 10 points (Additional file 1: Table S1).
The somatic parameters comprised bone mineral dens-
ity (BMD) (20 points), waist circumference (10 points),
low-density lipoprotein cholesterol (LDL-C) (10 points),
and body fat mass (10 points). Details on the allocation of
the GET score points for the somatic parameters are pro-
vided in Additional file 1: Table S3.
Dual-energy X-ray absorptiometry (DXA) is the gold
standard for BMD measurement [3, 12]. As patients’ ages
spanned more than five decades, the z-score was selected
as the most suitable parameter for measuring BMD. The
most pronounced effect of GH substitution on BMD is
detectable at the lumbar spine [13], hence this was the
measuring site for the GET score. Based on published data
[14], DXA BMD lumbar spine z-score ≤ −2 was assigned a
score of 0 points, and a z-score ≥ 0 was assigned a score of
20 points.
Waist circumference reflects visceral fat accumulation
and is established as a key criterion for the diagnosis of
metabolic syndrome and as an independent cardiovascular
risk factor [15]. When including this parameter in the GET
score, individual variance, risk threshold, and published
data from patients with AGHD with rather small thera-
peutic effects had to be considered [16, 17]. Therefore,
waist circumference ≥99 cm in females / ≥113 cm in males
scored 0 points, and waist circumference ≤ 80 cm in fe-
males / ≤94 cm in males scored 10 points.
Based on the baseline values and the therapeutic ef-
fects of GH substitution on LDL-C in patients with
AGHD [18, 19], LDL-C ≥ 3.98 mmol/L (154 mg/dL)
scored 0 points, and ≤2.59 mmol/L (100 mg/dL) scored
10 points.
Using a Tanita scale, body fat mass can be assessed with
body impedance analysis. Based on data from Rosenfalck
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et al. [20], body fat mass percentage ≥ 44.1% scored 0
points, and ≤21.5% scored 10 points.
To calculate a GET score, the first step is to calculate
the overall SF-36 GET score points by taking the average
of all eight SF-36 GET score points based on the trans-
formed SF-36 domain scores (Additional file 1: Table S1).
The second step is to add the GET score points for the
remaining HRQoL parameters – EQ-5D-VAS and
disease-related days off work (Additional file 1: Table S1).
The third step is to look up the GET score points for the
somatic parameters using the GET score points as shown
in Additional file 1: Table S3. The addition of all compo-
nents sums up to the final GET score. An example of a
calculation of GET score is provided in Additional file 1:
Table S4. If individual parameters are missing, the score is
calculated without these parameters, but adjusted accord-
ingly (Additional file 1: Table S5). For example, BMD has
a weighting of 20%; the maximum score achievable with-
out BMD would be 80. If a patient achieved a determined
score of 67 without BMD, adjustment of the determined
score would be 67/80*100, resulting in a final GET score
of 83.75 (Additional file 1: Table S5). A minimum number
of parameters giving a total weighting of ≥70% is required
to determine the adjusted GET score, otherwise the GET
score is set to missing.
Proof of concept study
Study design
GH-treatment-naïve patients with AGHD, defined ac-
cording to GH Research Society criteria [3], under the
care of endocrinologists, were enrolled into a prospect-
ive, observational, non-interventional, multicentre proof
of concept study.
The indication and clinical decisions regarding GH re-
placement (Norditropin® [somatropin, recombinant human
GH], Novo Nordisk A/S, Denmark) were made by the
treating physician according to usual clinical practice. GH-
treated patients were compared with patients in whom no
treatment was initiated; the decision not to initiate GH re-
placement was taken jointly by the patient and the phys-
ician. The study was performed in accordance with the
Declaration of Helsinki [21]. Ethical permissions were ob-
tained from the Ethical Commission of the Chamber of
Physicians of the German Federal State of Hessia. Informed
consent was obtained from all study participants.
The study recruitment period was originally planned
for 24 months, but extended to 36 months due to lim-
ited recruitment. Participation commenced at visit 1,
when baseline data were collected and GH treatment
was initiated in the treatment group. Interim follow-up
visits (visits 2–4) were planned for approximately every
6 months, but occurred at varying intervals, and the par-
ticipants’ involvement concluded at visit 5. If the patient
prematurely discontinued participation, the last interim
visit became the final visit. Duration of follow-up was
calculated as days between first and last visit.
The inclusion criteria for data analysis were availability
of baseline demographic data (gender, date of birth), in-
formation about GH therapy for treated patients and at
least one of four follow-up visits.
The GET score was calculated, and if there were too
few parameters to provide a total weighting of ≥70%,
the GET score was set to missing. In the proof of con-
cept study, IGF-I concentrations were measured mainly
as a parameter for plausibility, verifying whether GH
had or had not been administered. IGF-I was assessed
centrally using the iSYS automated chemiluminescent
IGF-I assay (Immunodiagnostic Systems Ltd., Boldon,
UK). The assay employs two monoclonal antibodies
and is calibrated against WHO International Standard
02/254 (National Institute for Biological Standards and
Control, Hertfordshire, UK) [22].
Statistical analysis
In observational studies, clinical practice is reflected in
missing values, missing visits and fewer untreated con-
trols than treated patients, thereby providing unbalanced
data; therefore, a repeated measures model was found to
be the most appropriate method to analyse the available
data. The study sample size was determined by the abil-
ity to recruit patients within the study period. By using
the repeated measures multiple regression model for the
GET score analysis, correlation of data within the indi-
vidual patient were taken into account when patients
were observed at several visits over time within the
study period. Any overall differences between the mean
GET score of the two groups in the full study period
could be detected. Due to the ageing of the patients over
the study period, deterioration over time could poten-
tially occur in the parameters included in the GET score,
therefore untreated controls versus treated patients were
evaluated.
The model included treatment group (control and
treated), visit, and the interaction term between visit and
treatment as explanatory variables. Gender, age and
treatment duration were also included in the model to
adjust for potential differences in patient characteristics
in the two groups. The overall difference in GET score
between control and treated groups in the full study
period was estimated by least squares means (LSM).
Missing data were handled by the repeated measures
model when evaluating the GET score and were consid-
ered missing completely at random. Descriptive statistics
were applied for all parameters and data are presented
as mean ± SD, unless otherwise stated. Statistical analysis
was performed using SAS v9.4 (SAS Institute Inc., Cary,
North Carolina, USA).
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Results
A total of 106 patients were eligible for analysis (con-
trols: 9 females, 13 males; GH-treated: 31 females, 53
males). Baseline characteristics for all 106 patients and
mean GH starting dose for treated patients are shown in
Table 1. A baseline GET score could only be calculated
for 75 patients due to missing data. In the follow-up
evaluation of the GET score the 75 patients were distrib-
uted as 15 control (5 females, 10 males) and 60 GH-
treated (22 females, 38 males) patients.
At baseline, where all patients were in a GH-naïve
stage, the overall mean ± SD GET score was estimated as
51.66 ± 20.48 score points, which was close to the
intended mean baseline score of around 50 and intended
SD of 20.
Baseline mean age was higher in the control versus the
treated group and higher in males than females; how-
ever, the statistical model adjusted for this. Differences
in age and gender did not reach a statistically significant
level when included in the full repeated measures model
evaluating the GET score.
Treatment (study) duration was longer for treated females
(706.5 ± 258 days) versus treated males (653.6 ± 242 days).
However, based on the results from the model, duration did
not have a statistically significant effect on the GET score
within the given study period.
GET score
Mean unadjusted GET scores by gender at baseline and
follow-up visits are shown in Table 2. Mean baseline
GET scores were close to 50 in all groups (female con-
trols: 51.14 ± 21.62; treated females: 47.02 ± 22.29; male
controls: 49.78 ± 19.01; treated males: 54.92 ± 19.84).
Fig. 1 shows the estimated GET scores for each group
at every visit based on the repeated measures model.
The analysis showed that GH treatment had an overall
clinically relevant and statistically significant effect on
the GET score of the expected magnitude, with a LSM
difference of + 10.01 ± 4.01 (p = 0.0145) between the
control and treated groups based on the full follow-up
period in the study.
Changes in individual items contributing to the GET score
HRQoL Improvements in HRQoL, as assessed with the
SF-36, were observed in the GH-treated group for physical
functioning (female + 4.64 ± 24.14 [n = 14]; male + 0.96 ±
14.42 [n = 26]), emotional role functioning (female + 5.36
± 25.66 [n = 14]; male + 1.92 ± 30.49 [n = 26]) and physical
role functioning (female + 12.05 ± 26.00 [n = 14]; male +
1.39 ± 20.17 [n = 27]); and in the female treated group
only there were improvements in their general health per-
ception (+ 10.93 ± 23.43 [n = 14]) and vitality (+ 9.82 ±
19.41 [n = 14]).
Using the EQ-5D-VAS, HRQoL was numerically higher
at baseline in female controls (n = 6) (77.67 ± 25.32) versus
treated females (n = 31) (58.71 ± 21.08), but numerically
lower in male controls (n = 11) (56.36 ± 19.38) than treated
males (n = 47) (65.15 ± 19.29). During the study period,
mean EQ-5D-VAS score increased in GH-treated patients
(mean change + 10.00 ± 11.73 females [n = 13]; + 6.38 ±
17.20 males [n = 26]). However, the score decreased sub-
stantially in female controls (n = 2) (mean change − 27.50
± 3.54) and increased slightly in male controls (n = 6) (+
4.33 ± 14.32). HRQoL assessed by the SF-36 was more vari-
able than when assessed by the EQ-5D-VAS.
Disease-related days off work The number of disease-
related days off work during the previous 6 months var-
ied throughout the study. There was a decrease at each
Table 1 Baseline demographics and characteristics of the included AGHD patients
Measurement Female control group Female treated group Male control group Male treated group
N Mean ± SD N Mean ± SD N Mean ± SD N Mean ± SD
Age (years) 9 51.60 ± 16.76 31 44.86 ± 13.05 13 57.16 ± 12.88 53 48.73 ± 14.69
GH starting dose (mg/day) 9 0.00 ± 0.00 31 0.23 ± 0.13 13 0.00 ± 0.00 53 0.20 ± 0.09
IGF-I SDS 9 −1.13 ± 2.09 26 −1.40 ± 1.44 12 −1.58 ± 1.17 44 −1.28 ± 1.72
Diagnosis at baseline 9 31 13 53
Acquired GHD (trauma) 1 1 0 1
Acquired GHD (pituitary tumour) 4 9 7 25
Acquired GHD (surgery/irradiation) 1 14 5 10
Acquired GHD (other) 2 4 0 6
Idiopathic GHD 1 0 0 5
Hypopituitarism/pituitary abnormality 0 3 1 5
Craniopharyngioma 0 0 0 1
AGHD adults with growth hormone deficiency, GET Growth hormone deficiency and Efficacy of Treatment, GH growth hormone, GHD GH deficiency, IGF-I insulin-
like growth factor 1, N number of participants eligible for analysis,SD standard deviation, SDS standard deviation score
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visit for GH-treated female patients, and the change
from baseline was − 30.00 ± 63.44 days by visit 5 (n = 5).
There was no discernible pattern in the number of
disease-related days off in the male treated group; num-
ber of days off was 8.21 ± 44.04 days below baseline at
visit 5 (n = 19).
Bone mineral density At baseline BMD assessed by
DXA z-score was − 0.54 ± 1.42 in female controls (n = 5),
− 0.20 ± 1.30 in male controls (n = 9), − 0.23 ± 1.06 in
treated females (n = 9) and − 0.68 ± 1.86 in treated males
(n = 20). There were small fluctuations throughout the
study, with minimal change from baseline by visit 5: fe-
male controls (n = 2): + 0.05 ± 0.21; male controls (n = 3):
+ 0.27 ± 0.45; treated females (n = 4): + 0.18 ± 0.59; treated
males (n = 9): + 0.49 ± 0.45. However, the small number of
patients who underwent DXA analysis made these data
difficult to interpret.
Waist circumference During the study, waist circum-
ference (cm) increased in controls (females [n = 6] +
2.67 ± 5.28; males [n = 5] + 3.86 ± 4.84) and decreased in
GH-treated patients (change from baseline [cm]: female
[n = 7] –2.86 ± 5.15; males [n = 20] –1.23 ± 7.55).
LDL-C During the study, LDL-C increased slightly from
baseline for female controls (n = 9) and all male patients
(n = 12) (female controls + 0.40 ± 0.82 mmol/L [n = 5];
male controls + 0.04 ± 0.72 mmol/L [n = 7]; treated males
+ 0.01 ± 0.63 mmol/L [n = 23]) and decreased slightly for
treated females (− 0.22 ± 0.68 mmol/L [n = 13]).
Body fat mass Baseline body fat mass (%) was higher in
females (controls: 32.98 ± 6.22 [n = 5]; treated: 36.81 ±
6.86 [n = 24]) than males (controls: 27.69 ± 8.68 [n = 11];
treated: 26.02 ± 6.55 [n = 47]). Absence of treatment was
associated with an increase in body fat (mean change
from baseline: female: + 0.85% ± 1.06% [n = 11]; male +
3.46% ± 3.07% [n = 47]), whereas GH treatment was as-
sociated with a decrease (mean change from baseline: fe-
male: − 2.29% ± 4.14% [n = 15]; male: − 1.93% ± 4.52%
[n = 27]).
IGF-I SDS The increase in GET score was accompanied
by an increase in IGF-I SDS in the GH-treated groups.
Mean IGF-I SDS was below zero (− 1.13 to − 1.58) for
all groups at baseline. At visit 2, change from baseline
for treated females was + 1.37 ± 1.14 (n = 23), and for
treated males was + 1.42 ± 1.21 (n = 39) (Fig. 2). The in-
creased level of IGF-I SDS in the treated groups was
maintained throughout the study. IGF-I SDS did not
substantially change for the control group, remaining
below zero at every visit.
Discussion
This study aimed to design and evaluate an experimental
score that integrates the different features of AGHD and
demonstrates the pleiotropic therapeutic effects of GH
substitution in patients with AGHD. The GET score,
which was designed based on evidence in the literature
[2, 3], weights items according to their clinical relevance
as considered by the study group. Importantly, the GET
Table 2 Meana GET score at baseline and follow-up visits by gender for GH-treated patients and controls
GET score
Visit Female control group Female treated group Male control group Male treated group
N Mean ± SD N Mean ± SD N Mean ± SD N Mean ± SD
1 (baseline) 5 51.14 ± 21.62 22 47.02 ± 22.29 10 49.78 ± 19.01 38 54.92 ± 19.84
2 5 48.84 ± 13.26 19 51.45 ± 13.07 10 47.02 ± 13.76 33 57.68 ± 16.47
3 4 53.49 ± 10.96 19 52.48 ± 16.09 9 43.22 ± 18.31 32 60.97 ± 14.92
4 3 43.65 ± 24.66 12 47.60 ± 14.70 9 40.58 ± 11.79 24 58.57 ± 13.91
5 3 49.84 ± 23.29 11 47.59 ± 14.11 6 49.19 ± 17.32 29 56.03 ± 14.67
aNote the data presented are crude mean values and based on a variable number of patients
GH growth hormone,GET Growth hormone deficiency and Efficacy of Treatment, N number of participants in whom GET score was calculated, SD
standard deviation
Fig. 1 Estimated difference in the GET score between control
and GH-treated groups during follow-up visits (EAS)EAS, effectiveness
analysis set; GET, Growth hormone deficiency and Efficacy of Treatment;
GH, growth hormone.
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score can potentially be applied and calculated by physi-
cians in everyday clinical practice.
However, our non-interventional study has shown that
in a considerable proportion of patients the GET score at
baseline could not be calculated due to missing data. This
was surprising since the score was designed so that a GET
score could be calculated with a total weighting of vari-
ables of only 70%, to account for potential missing data in
a real world setting. The mean baseline GET score in GH-
untreated patients was ~ 50, with a variation equivalent to
~ 20 points (SD). The contribution for each individual
item to the observed GET scores was appropriately spread
across the score range (i.e., 0–10 or 0–20, depending on
the weighting) and mean scores were positioned, as ex-
pected, around the midpoint of the scale, indicating that
the predefined score calculation was suitable. The descrip-
tive statistics of the GET score in a GH treatment naïve
situation at baseline yielded results within the expected
range, indicating that the assumptions made when design-
ing the score were appropriate.
In our proof of concept study, the GET score was eval-
uated and used to estimate the combined pleiotropic ef-
fects of GH by calculating the overall difference in GET
score in the full follow-up period between the untreated
versus treated group. This required the use of a repeated
measures model to account for correlation of data
within the individual patient, to handle missing and thus
variable numbers of observations, and to detect any
overall differences between mean GET scores of the two
groups in the full study period. Due to the longitudinal
nature of the study, interpretation of the study should be
based on the overall difference between the two groups,
as estimated by the model and shown in Fig. 1.
Based on the full follow-up period of the study, the GET
score was statistically significantly different overall be-
tween untreated and GH-treated patients in the expected
range of ~ 10 points, representing a clinically relevant
difference in HRQoL and/or somatic parameters. This dif-
ference was largely driven by the deterioration in GET
score over time in the untreated group. The difference
reached the magnitude expected, confirming that the as-
sumptions made when designing the score were appropri-
ate. This allows us to state that the GET score may be a
suitable instrument to quantify the effects of GH treat-
ment in patients with AGHD in an integrative way.
The GET score includes clinically relevant parameters,
weighted according to potential impact on the individual
patient. Patients with AGHD have reported the negative
impact of their condition on many aspects of daily life
[23], and the importance of HRQoL is recognised in
clinical practice guidelines [24, 25]. Hence, the HRQoL
parameters provide the highest overall contribution to
the GET score (40%). Although the sample size of this
study is limited, the results are consistent with available
literature showing that GH substitution can positively
influence HRQoL [26, 27].
BMD contributed significantly to the GET score
(weighted 20%); however, unfortunately only a small num-
ber of patients in this study underwent DXA analysis, mak-
ing interpretation of the data difficult. Many patients lacked
BMD data because data collection was based on routine
clinical practice and not a study protocol. During this study,
BMD assessed by DXA z-score did not change significantly.
Davidson et al. [28] demonstrated that clinically significant
changes in BMD are observed after treatment duration of
at least 18–24 months. This limitation could be addressed
by studying a larger cohort over a longer period.
IGF-I serum levels are used for GH dose titration
[24, 25] and provide an indication of the efficacy of
GH therapy and patients’ adherence with treatment.
In this study, IGF-I SDS increased from baseline to
near zero by visit 2 following GH treatment initiation;
this level was maintained or increased throughout the
study in the treated groups.
Fig. 2 Mean (SD) change in IGF-I SDS from baseline to follow-up visits by genderIGF-I, insulin-like growth factor 1; SD, standard deviation; SDS,
standard deviation score.
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The main limitation of this proof-of-concept study was
the observational, non-interventional design, which lacked
the methodological rigour of a randomised controlled trial.
The control group had a low number of patients and there
were also differences between groups; it is likely that, as the
decision for treatment was based on physician opinion, the
two groups (control and treated) were not homogeneous,
with differences in co-morbidities and use of concomitant
medication. Treatment adherence was not evaluated in the
treatment group, which may have affected the results.
As with many observational studies, missing data were a
challenge, and incomplete data sets had to be handled by
an appropriate statistical approach. The set of parameters
chosen for the GET score was based on published evi-
dence; however, in contrast to the published recommen-
dations [3] these parameters do not seem to be routinely
assessed when GH-treatment is warranted in AGHD. The
small number of BMD examinations was unexpected for
the study group. Potentially, the study duration was too
short for BMD follow-up examinations. The fact that a
baseline GET score could only be calculated in 75/106 pa-
tients is a concern regarding the ability of the GET score
to be used in everyday clinical practice. The process of cal-
culating the GET score, particularly the points for SF-36,
is laborious, thus limiting the use in routine clinical prac-
tice. Nevertheless, an individual comparison of GET scores
at baseline and after a period of GH treatment might be of
clinical relevance for the assessment of individual clinical
response to GHT.
Conclusions
The newly developed GET score appeared to be a suitable
instrument to summarise the features of AGHD and
evaluate the pleiotropic response to GH substitution ther-
apy in an integrated way. We suggest the GET score as a
tool for clinical studies rather than for routine clinical
practice. A further study in a larger cohort and over a lon-
ger period of time could overcome some of the shortcom-
ings seen in this project.
Additional file
Additional file 1: Table S1. GET score point allocation for HRQoL
parameters (which comprise 50 of the total of 100 points of the GET
score). Table S2 Example of a calculation of SF-36 GET score component
points. Table S3 GET score point allocation for somatic parameters (which
comprise 50 of the total of 100 points of the GET score).Table S4 Example
of calculation of GET score including SF-36 subtotal and addition to other
components of the score. GET score calculation. Table S5 Example of
calculation of an adjusted GET score due to a missing value (DOCX 39 kb)
Abbreviations
AGHD: Adults with growth hormone deficiency; BMD: Bone mineral density;
DXA: Dual-energy X-ray absorptiometry; EBM: Evidence-based medicine; EQ-
5D: EuroQol five dimensions questionnaire; EQ-5D-VAS: VAS component of
EQ-5D; GET score: Growth hormone deficiency and Efficacy of Treatment
score; GH: Growth hormone; GHD: Growth hormone deficiency;
HRQoL: Health-related quality of life; IGF-I: Insulin-like growth factor I; LDL-
C: Low-density lipoprotein cholesterol; LSM: Least squares means;
SD: Standard deviation; SDS: Standard deviation score; SF-36: Short-Form
Health Survey 36; VAS: Visual analogue scale
Acknowledgements
The authors thank the representatives of a total of 28 centres for
endocrinology in Germany that contributed patients’ data to the non-
interventional clinical study. The authors also thank Stefan Kipper (Novo Nordisk
Pharma GmbH, Mainz, Germany) for his invaluable contribution to this project,
Judith L. Jacobsen (Statcon, Denmark) for perfect technical and statistical support,
and Lise Højbjerre (Novo Nordisk A/S, Denmark) for review of the manuscript.
Medical writing and submission support were provided by Grace Townshend and
Richard McDonald of Watermeadow Medical, funded by Novo Nordisk Pharma
GmbH, Mainz, Germany.
Funding
This study was sponsored by Novo Nordisk Pharma GmbH, Mainz, Germany.
NCT number: NCT00934063.
Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly
available but are available from the corresponding author on reasonable request.
Authors’ contributions
PHK contributed to research design, acquisition of data, analysis/
interpretation of data, revised the manuscript critically, and approved the
final version. SB contributed to acquisition of data, analysis/interpretation of
data, revised the manuscript critically, and approved the final version. MB
contributed to acquisition of data, analysis/interpretation of data, revised the
manuscript critically, and approved the final version. CD contributed to
acquisition of data, analysis/interpretation of data, revised the manuscript
critically, and approved the final version. BTP contributed to analysis/
interpretation of data, revised the manuscript critically, and approved the
final version. GKS contributed to research design, acquisition of data,
analysis/interpretation of data, revised the manuscript critically, and
approved the final version. MMW contributed to research design, acquisition
of data, analysis/interpretation of data, revised the manuscript critically, and
approved the final version. SMF contributed to analysis/interpretation of
data, revised the manuscript critically, and approved the final version.
Ethics approval and consent to participate
This study was performed in accordance with the Declaration of Helsinki.
Ethical permissions were obtained from the Ethical Commission of the
Chamber of Physicians of the German Federal State of Hessia (reference no
FF 22/2009).
Written and informed consent for the registration and transfer of their personal
data was obtained from all patients.
Consent for publication
Not applicable.
Competing interests
PHK has received research funding, honoraria for lectures and is a member
of scientific boards for Novo Nordisk and Pfizer. MB has received research
support, consultancy fees and/or speakers honoraria from Novo Nordisk,
Pfizer, Sandoz, Novartis, IPSEN, OPKO and Genexine. BTP is an employee of
Novo Nordisk A/S, Denmark. GKS has received speaker fees from Novo
Nordisk and study investigator sponsored by Novo Nordisk. MMW is member
of the NordiNet® ISC Board Novo Nordisk. SM-F is an employee and stockholder
of Novo Nordisk Pharma GmbH, Germany. SB and CD have no conflicts
of interest to declare.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Division of Endocrinology & Diabetology, Philipp’s University Marburg,
D-35033 Marburg, Germany. 2Endocrine Laboratory, Medizinische Klinik und
Poliklinik IV, Ludwig-Maximilians University, 80336 Munich, Germany.
Kann et al. BMC Endocrine Disorders  (2018) 18:10 Page 7 of 8
3Neuroendocrinology, Max-Planck-Institute for Psychiatry, 80804 Munich,
Germany. 4Epidemiology, Novo Nordisk A/S, 2860 Søborg, Denmark.
5Endocrinology & Metabolism, Johannes Gutenberg University Hospital,
55131 Mainz, Germany. 6Clinical, Medical & Regulatory Department, Novo
Nordisk Pharma GmbH, 55127 Mainz, Germany.
Received: 13 September 2017 Accepted: 1 February 2018
References
1. Carroll PV, Christ ER, Bengtsson BA. Growth hormone research society
scientific committee. Growth hormone deficiency in adulthood and the
effects of growth hormone replacement: a review. J Clin Endocrinol Metab.
1998;83:382–95.
2. Fassbender WJ, Brabant G, Buchfelder M, et al. Treatment of proven growth
hormone deficiency in adults with recombinant human growth hormone
according to evidence-based criteria. Dtsch Med Wochenschr. 2005;130:
2589–95.
3. Ho KK. 2007 GH deficiency consensus workshop participants. Consensus
guidelines for the diagnosis and treatment of adults with GH deficiency II: a
statement of the GH research society in association with the European
Society for Pediatric Endocrinology, Lawson Wilkins society, European
Society of Endocrinology, Japan Endocrine Society, and Endocrine Society
of Australia. Eur J Endocrinol. 2007;157:695–700.
4. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose
lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
5. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and
vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:
2560–72.
6. Ware JE Jr. SF-36 health survey update. 2007. http://www.sf-36.org/tools/
SF36.shtml. Accessed July 2017.
7. Koltowska-Haggstrom M, Jonsson B, Isacson D, et al. Using EQ-5D to derive
general population-based utilities for the quality of life assessment of growth
hormone deficiency in adults (QoL-AGHDA). Value Health. 2007;10:73–81.
8. Busschbach JJ, Wolffenbuttel BH, Annemans L, et al. Deriving reference
values and utilities for the QoL-AGHDA in adult GHD. Eur J Health Econ.
2011;12:243–52.
9. Valassi E, Brick DJ, Johnson JC, et al. Effect of growth hormone replacement
therapy on the quality of life in women with growth hormone deficiency
who have a history of acromegaly versus other disorders. Endocr Pract.
2012;18:209–18.
10. McKenna SP, Doward LC, Alonso J, et al. The QoL-AGHDA: an instrument for
the assessment of quality of life in adults with growth hormone deficiency.
Qual Life Res. 1999;8:373–83.
11. Saller B, Mattsson AF, Kann PH, et al. Healthcare utilization, quality of life
and patient-reported outcomes during two years of GH replacement
therapy in GH-deficient adults – comparison between Sweden, The
Netherlands and Germany. Eur J Endocrinol. 2006;154:843–50.
12. Rosenfeld RG, Cohen P, Robison LL, et al. Long-term surveillance of growth
hormone therapy. J Clin Endocrinol Metab. 2012;97:68–72.
13. Kann P, Piepkorn B, Schehler B, et al. Effect of long-term treatment with GH
on bone metabolism, bone mineral density and bone elasticity in GH-
deficient adults. Clin Endocrinol. 1998;48:561–8.
14. Kann PH. Clinical effects of growth hormone on bone: a review. Aging
Male. 2004;7:290–6.
15. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide
definition. Lancet. 2005;366:1059–62.
16. Zhu S, Heymsfield SB, Toyoshima H, et al. Race-ethnicity-specific waist
circumference cutoffs for identifying cardiovascular disease risk factors. Am J
Clin Nutr. 2005;81:409–15.
17. Franco C, Johannsson G, Bengtsson BA, et al. Baseline characteristics and effects
of growth hormone therapy over two years in younger and elderly adults with
adult onset GH deficiency. J Clin Endocrinol Metab. 2006;91:4408–14.
18. Abs R, Feldt-Rasmussen U, Mattsson AF, et al. Determinants of cardiovascular
risk in 2589 hypopituitary GH-deficient adults – a KIMS database analysis. Eur J
Endocrinol. 2006;155:79–90.
19. van der Klaauw AA, Romijn JA, Biermasz NR, et al. Sustained effects of
recombinant GH replacement after 7 years of treatment in adults with GH
deficiency. Eur J Endocrinol. 2006;155:701–8.
20. Rosenfalck AM, Maghsoudi S, Fisker S, et al. The effect of 30 months of low-dose
replacement therapy with recombinant human growth hormone (rhGH) on
insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose
effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol
Metab. 2000;85:4173–81.
21. Divall SA, Radovick S. Growth hormone and treatment controversy; long
term safety of rGH. Curr Pediatr Rep. 2013;1:128–32.
22. Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like
growth factor-1 (IGF-I) from birth to senescence: results from a multicenter
study using a new automated chemiluminescence IGF-I immunoassay
conforming to recent international recommendations. J Clin Endocrinol Metab.
2014;99:1712–21.
23. Brod M, Pohlman B, Hojbjerre L, et al. Impact of adult growth hormone
deficiency on daily functioning and well-being. BMC Res Notes. 2014;7:813.
24. ClinicalTrials.gov. A Prospective Observational Study of Effect of Somatropin
on Growth Hormone Deficient Adults (HypoCCS). 2016. https://clinicaltrials.
gov/ct2/show/NCT01088399. Accessed July 2017.
25. Cook DM, Yuen KC, Biller BM, et al. American Association of Clinical
Endocrinologists medical guidelines for clinical practice for growth hormone
use in growth hormone-deficient adults and transition patients – 2009 update.
Endocr Pract. 2009;15(Suppl 2):1–29.
26. Degerblad M, Almkvist O, Grunditz R, et al. Physical and psychological
capabilities during substitution therapy with recombinant growth hormone in
adults with growth hormone deficiency. Acta Endocrinol. 1990;123:185–93.
27. Hull KL, Growth HS. Hormone therapy and quality of life: possibilities, pitfalls
and mechanisms. J Endocrinol. 2003;179:311–33.
28. Davidson P, Milne R, Chase D, et al. Growth hormone replacement in adults
and bone mineral density: a systematic review and meta-analysis. Clin
Endocrinol. 2004;60:92–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kann et al. BMC Endocrine Disorders  (2018) 18:10 Page 8 of 8
